Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F M Wigley

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Arthritis and Rheumatism|June 12, 1999
Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosisS P Atamas, V V Yurovsky, R Wise, et al.
Arthritis and Rheumatism|March 7, 2001
The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigenL A Casciola-Rosen, A F Pluta, P H Plotz, et al.
Controlled Clinical Trials|February 23, 1999
Behavioral and pharmacologic interventions: the Raynaud's Treatment StudyB Thompson, N L Geller, S Hunsberger, et al.
The Journal of Rheumatology|January 1, 1994
Comparison of aminobenzoate potassium and placebo in the treatment of sclerodermaD O Clegg, J C Reading, M D Mayes, et al.
Journal of Clinical Epidemiology|June 9, 1999
Symptoms of Raynaud's phenomenon in an inner-city African-American community: prevalence and self-reported cardiovascular comorbidityA C Gelber, F M Wigley, R Y Stallings, et al.
The Journal of Rheumatology|March 7, 1998
Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosisJ R Seibold, P J Clements, D E Furst, et al.
The European Respiratory Journal|August 1, 2009
Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertensionS C Mathai, M Bueso, L K Hummers, et al.
Annals of Internal Medicine|February 1, 1994
Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind studyF M Wigley, R A Wise, J R Seibold, et al.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Arthritis and Rheumatism|April 25, 2001
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)J H Stone, G S Hoffman, P A Merkel, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Arthritis and Rheumatism|June 12, 1999
Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosisS P Atamas, V V Yurovsky, R Wise, et al.
Arthritis and Rheumatism|March 7, 2001
The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigenL A Casciola-Rosen, A F Pluta, P H Plotz, et al.
Controlled Clinical Trials|February 23, 1999
Behavioral and pharmacologic interventions: the Raynaud's Treatment StudyB Thompson, N L Geller, S Hunsberger, et al.
The Journal of Rheumatology|January 1, 1994
Comparison of aminobenzoate potassium and placebo in the treatment of sclerodermaD O Clegg, J C Reading, M D Mayes, et al.
Journal of Clinical Epidemiology|June 9, 1999
Symptoms of Raynaud's phenomenon in an inner-city African-American community: prevalence and self-reported cardiovascular comorbidityA C Gelber, F M Wigley, R Y Stallings, et al.
The Journal of Rheumatology|March 7, 1998
Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosisJ R Seibold, P J Clements, D E Furst, et al.
The European Respiratory Journal|August 1, 2009
Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertensionS C Mathai, M Bueso, L K Hummers, et al.
Annals of Internal Medicine|February 1, 1994
Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind studyF M Wigley, R A Wise, J R Seibold, et al.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Arthritis and Rheumatism|April 25, 2001
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)J H Stone, G S Hoffman, P A Merkel, et al.
Pageof 10